Cargando…

Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584390/ https://www.ncbi.nlm.nih.gov/pubmed/36264846 http://dx.doi.org/10.1371/journal.pone.0276650

Ejemplares similares

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
por: Shah, Manish A., et al.
Publicado: (2021)

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
por: Shah, Manish A., et al.
Publicado: (2022)

Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer
por: Kogata, Yuhei, et al.
Publicado: (2018)

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Seiwert, Tanguy, et al.
Publicado: (2012)

Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models
por: Grojean, Meghan, et al.
Publicado: (2021)

The Role of cMET in Gastric Cancer—A Review of the Literature
por: Van Herpe, Filip, et al.
Publicado: (2023)

Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
por: Ohara, Masahiro, et al.
Publicado: (2021)

Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma
por: Lohberger, Birgit, et al.
Publicado: (2021)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
por: Venepalli, Neeta K., et al.
Publicado: (2013)

Role of cMET in the Development and Progression of Colorectal Cancer
por: Pérez-Vargas, Juan Carlos Samamé, et al.
Publicado: (2013)

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
por: Hassan, Md. Sazzad, et al.
Publicado: (2019)

Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling
por: Sohn, Sung-Hwa, et al.
Publicado: (2020)

Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling
por: Chen, Hsiu-Mei, et al.
Publicado: (2015)

Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met
por: Chen, Guang-Zong, et al.
Publicado: (2017)

Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor
por: Sakr, Hany I, et al.
Publicado: (2015)

Urinary cMet as a prognostic marker in immunoglobulin A nephropathy
por: An, Jung Nam, et al.
Publicado: (2020)

Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy
por: Kim, Ki-Hyun, et al.
Publicado: (2017)

Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors
por: Collie, Gavin W., et al.
Publicado: (2019)

Renoprotective effects of a novel cMet agonistic antibody on kidney fibrosis
por: Kim, Yong Chul, et al.
Publicado: (2019)

The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer
por: Armstrong, Gemma R., et al.
Publicado: (2021)

Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients
por: Machiraju, Devayani, et al.
Publicado: (2023)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
por: Kim, Yong Chul, et al.
Publicado: (2018)

cMet agonistic antibody attenuates apoptosis in ischaemia‐reperfusion–induced kidney injury
por: An, Jung Nam, et al.
Publicado: (2020)

Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis
por: Ye, Peng, et al.
Publicado: (2015)

Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer
por: Lu, Jun, et al.
Publicado: (2015)

56. Foretinib Enhances Myelination of Neurons in Vitro
por: Mirmoeini, Kaveh, et al.
Publicado: (2023)

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
por: Van Der Steen, Nele, et al.
Publicado: (2015)

Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
por: Singh, Ratnakar, et al.
Publicado: (2019)

Detection of colonic neoplasia in vivo using near-infrared-labeled peptide targeting cMet
por: Wu, Xiaoli, et al.
Publicado: (2019)

EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming
por: Meng, Fanyan, et al.
Publicado: (2019)

The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker
por: Klotz, Daniel Martin, et al.
Publicado: (2021)

The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model
por: Spiegelberg, Diana, et al.
Publicado: (2020)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
por: Simiczyjew, Aleksandra, et al.
Publicado: (2018)

The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer
por: Chae, Young Kwang, et al.
Publicado: (2016)

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells
por: Vengoji, Raghupathy, et al.
Publicado: (2019)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer
por: Ibarrola-Villava, Maider, et al.
Publicado: (2015)

cMetS Based on Z-Scores as an Accurate and Efficient Scoring System to Determine Metabolic Syndrome in Spanish Adolescents
por: Fernández-Aparicio, Ángel, et al.
Publicado: (2022)

The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
por: Carvalho, Bruno, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u791q7v51u7cir5r9hc7mjk5q5